Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Corticosteroids
7 evidence topics · 4 sources
Recommendations for corticosteroid induction and against corticosteroid maintenance: ACG 2025 guideline
Efficacy of systemic corticosteroids and budesonide MMX: ACG 2025 guideline
Recommendations for oral prednisolone and colonic-release corticosteroids: ECCO 2026 guideline
Indication and induction efficacy of budesonide extended-release tablets
Induction of remission in Studies 1 and 2 of budesonide extended-release tablets
| Treatment group | Study 1 n/N (%) | Study 2 n/N (%) |
|---|---|---|
| Budesonide 9 mg | “22/123 (17.9)” | “19/109 (17.4)” |
| Budesonide 6 mg | “16/121 (13.2)” | “9/109 (8.3)” |
| Placebo | “9/121 (7.4)” | “4/89 (4.5)” |
Warnings and precautions for budesonide extended-release tablets
Complications of chronic corticosteroid use in US adults with ulcerative colitis
“Patients with long-term or chronic use of CS may present with both short- and long-term complications including infection, hypertension, new-onset diabetes mellitus, osteoporosis, cataracts, and glaucoma.5,6” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although CS therapy is efficacious in inducing remission among most patients with UC, more than 90% of patients will experience an adverse event, and CS dependence is common.4,8,9” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of several CS-related complications among targeted treatment initiators was significantly higher in chronic CS users compared with nonchronic CS users, with proportions of 55.5% vs 52.4% for patients with infection, leading to an odds ratio (OR) of 1.14 (95% CI = 1.00-1.29; P = 0.0500); 14.5% vs 7.4% for bone loss, leading to an OR of 2.13 (95% CI = 1.72-2.64; P < 0.001); 5.6% vs 3.0% for venous thromboembolism, leading to an OR of 1.93 (95% CI = 1.39-2.68; P < 0.001); and 2.5% vs 0.3% for adrenocortical insufficiency, leading to an OR of 8.24 (95% CI = 3.50-19.37; P < 0.001; Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote